Objective: To evaluate the clinical outcomes and safety profile of intravitreal corticosteroid implants in managing non-infectious uveitis. Methods: A retrospective cohort study was conducted on 85 patients with non-infectious uveitis treated with intravitreal corticosteroid implants (dexamethasone or fluocinolone acetonide). Data were collected on best-corrected visual acuity (BCVA), central macular thickness (CMT), inflammation control, intraocular pressure (IOP), and adverse events over a 12-month follow-up period. Statistical analysis compared baseline and post-treatment outcomes. Results: BCVA improved from 20/100 at baseline to 20/50 at 6 months and 20/40 at 12 months, with 75% of patients achieving a ≥2-line improvement.CMT reduced significantly from 550 µm at baseline to 280 µm at 12 months (p < 0.001).Active inflammation (grades 2+ or higher) decreased from 92% at baseline to 5% at 12 months, with 80% achieving complete resolution.Cataract progression occurred in 40% of phakic eyes, with 18 requiring surgery. IOP elevation (>25 mmHg) was observed in 18% of patients, with 12% requiring treatment.78% reported improved visual function, and 85% expressed satisfaction with the treatment. Conclusions: Intravitreal corticosteroid implants are highly effective in improving vision, reducing macular edema, and controlling inflammation in non-infectious uveitis. While adverse effects such as cataract progression and IOP elevation are notable, they can be managed with appropriate follow-up. These implants represent a valuable option for patients requiring localized, long-term anti-inflammatory treatment.